



US005621123A

United States Patent [19]

Johnson et al.

[11] Patent Number: 5,621,123

[45] Date of Patent: *Apr. 15, 1997

[54] CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN

[75] Inventors: Roy A. Johnson, Kalamazoo; Gordon L. Bundy, Portage; Gilbert A. Youngdale, Portage; Douglas R. Morton, Portage; Donald P. Wallach, deceased, late of Kalamazoo; Vera M. Wallach, legal representative, Richland, all of Mich.

[73] Assignee: The Upjohn Company, Kalamazoo, Mich.

[*] Notice: The portion of the term of this patent subsequent to Feb. 16, 2010, has been disclaimed.

[21] Appl. No.: 247,169

[22] Filed: May 20, 1994

Related U.S. Application Data

[62] Division of Ser. No. 976,751, Nov. 16, 1992, Pat. No. 5,334,712, which is a division of Ser. No. 657,721, Feb. 20, 1991, Pat. No. 5,196,542, which is a division of Ser. No. 394,396, Aug. 15, 1989, abandoned, which is a division of Ser. No. 117,851, filed as PCT/US86/02116, Oct. 7, 1986, Pat. No. 4,917,826, which is a continuation-in-part of Ser. No. 843,120, filed 24, 1986, abandoned, which is a continuation-in-part of Ser. No. 788,995, Oct. 18, 1985, abandoned.

[51] Int. Cl. CMJ 41/00

[52] U.S. Cl. 552/522; 552/554

[58] Field of Search 540/112, 117; 552/522; 564/460

[56] References Cited

U.S. PATENT DOCUMENTS

3,084,156	411963	Counsell et al.
3,107,255	1011963	Counsell et al.
3,284,474	1111966	Klimstra .
3,284,475	1111966	Klimstra .
3,326,758	611967	Irmscher et al. 5521522
3,370,070	211968	Klimstra .
3,639,598	211972	Klimstra .
4,239,780	1211980	Wallach 424/330
4,330,539	511982	Sleigh et al. 5521522
5,075,434	1211991	Youngdale 540/106

FOREIGN PATENT DOCUMENTS

1074578	1211963	European Pat. Off..
1337759	711960	France .
1421230	1111965	France .
1187236	211965	Germany .
1074578	711967	United Kingdom.

OTHER PUBLICATIONS

W. Vogt, Advances in Prostaglandins and Thromboxane Research, 3:89-95 (1978).
 P.C. Isakson et al., Advances in Prostaglandin and Thromboxane Research, 3-113-120 (1978).
 N.A. Plummer et al., Journal of Investigative Dermatology, 68:246 (1977).
 B.B. Vargaftig, J. Pharm. Pharmacol., 29:222-228 (1977).

R.J. Flower et al, Nature, 278:456-459 (1979).

L. Kaplan et al, Proc. Natl. Acad. Sci., 75:2955-2988 (1978).

E. Vallee et al, J. Pharm. Pharmacol., 31:588-592 (1974).

M. Roberts et al., J. of Biol. Chem., 252:2405-2411 (1977).

G.J. Blackwell et al, British J. Pharmacy, 62:79-89 (1978).

D.P. Wallach et al, Bioch. Pharmacol., 30:1315-1324 (1981).

L.J. Griggs, "Part I. Synthetic Approaches to 5- and 16-Thi-aestrone. Part II. Estrone With a Diazacholesterol Side Chain", University of Michigan (1965).

P.D. Klimstra et al., J. Med. Chem., 9:323-326 (1966).
 Klimstra et al. Hypocholesterolenic Agents VI, May, 1966 pp. 323-325.

Grant and Hackh's Chemical Dictionary (New York, McGraw-Hill, 1987) p. 14.

Vogt, W, "Role of Phospholipase A₂ in Prostaglandin Formation", Advances in Prostaglandins and Thromboxane Research, 3, p. 89 (1978).

Isakson, P.C. et al., "Lipases and Prostaglandin Biosynthesis", Advances in Prostaglandin and Thromboxane Research, 3, p. 113, (1978).

Plummer, N.A., et al., "Activation of the Arachidonate Cascade in Human Skin Inflamed by Irradiation with UVC and the Effects of Indomethacin", abstracted in Journal of Investigative Dermatology, 68, p. 246 (1977).


Vargaftig,B.B., "Carrageenan and thrombin trigger prostaglandin synthetase-independent aggregation of rabbit platelets: inhibition by phospholipase A₂ inhibitors", J. Pharm. Pharmacol., 29, pp. 222-228 (1977).Flower, R.J. and Blackwell, G.J., "Anti-inflammatory steroids induce biosynthesis of a phospholipase A₂ inhibitor which prevents prostaglandin generation", Nature, 278, pp. 456-459 (1979).Kaplan, K.L., et al., "Low concentrations of indomethacin inhibit phospholipase A₂ of rabbit polymorphonuclear leukocytes", Proc. Natl. Acad. Sci., 75, pp. 2955-2988 (1978).
 Vallee, E., et al., "Anti-inflammatory and platelet anti-aggregant activity of phospholipase-A₂ inhibitors", J. Pharm. Pharmacol., 31, pp. 588-592 (1974).Roberts, M.F., et al., "Chemical Modification of the Histidine Residue in Phospholipase A₂", J. of Biol. Chem., 252, pp. 2405-2411 (1977).

(List continued on next page.)

Primary Examiner—Mukund J. Shah
 Assistant Examiner—Pavanaram K. Sripada
 Attorney, Agent, or Firm—Thomas A. Wootton

[57] ABSTRACT

Provided are cyclic hydrocarbons of Formula I

with an aminoalkyl sidechain that are useful for treating phospholipase A₂ mediated conditions, diabetes, and obesity.

OTHER PUBLICATIONS

Blackwell, G.J., et al., "Phospholipase A₂ Activity of Guinea-pig Isolated Perfusion Lungs: Stimulation, and Inhibition by Anti-Inflammatory Steroids", British J. Pharmacy, 62, pp. 79-89 (1978).

Wallach, D.P. and Brown, V.J.R., "Studies on the Arachidonic Acid Cascade-I", Bioch. Pharmacol., 30, pp. 1315-1324 (1981).

Doctoral thesis, L.J. Griggs, "Part I. Synthetic Approaches to 6- and 16-Thiaestrone. Part II. Estrone with a Diazacholesterol Side Chain," University of Michigan (1965).

Klimstra, P.D., et al., "Hypocholesterolemic Agents. VI. A- and B-Ring-Modified Azacholesterols", J. Med. Chem., 9, pp. 323-326 (1966).

1

CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 071976,751, filed 16 Nov. 1992, issued as U.S. Pat. No. 5,334,712 on 02 Aug. 1994, which was a division of application Ser. No. 071657,721, filed 20 Feb. 1991, issued as U.S. Pat. No. 5,196,542 on 23 Mar. 1993, which was a division of application Ser. No. 07/394,396, filed 15 Aug. 1989, now abandoned, which was a division of application Ser. No. 07/117,851, filed 16 Jun. 1987, now U.S. Pat. No. 4,917,826, which was the continuing national phase of International Patent Application No. PCT/US86/02116, International Filing Date, 7 Oct. 1986, which was a continuation-in-part of patent application Ser. No. 06/843,120, filed 24 Mar. 1986, now abandoned, which was a continuation-in-part of patent application Ser. No. 061788,995, filed 18 Oct. 1985, now abandoned.

FIELD OF INVENTION

This invention relates to novel compositions of matter. More particularly, the invention relates to cyclic hydrocarbons with an aminoalkyl sidechain that are useful for inhibiting phospholipase A2 and for treating diabetes and obesity.

INFORMATION DISCLOSURE

The important role of phospholipase A2 in mammalian metabolism through the formation of prostaglandins is now well known. See W. Vogt, Advances in Prostaglandins and Thromboxane Research, 3, p. 89 (1978); P. C. Isakson, et al., Advances in Prostaglandin and Thromboxane Research, 3, page 113, (1978). Phospholipase A2 is responsible for the hydrolysis of arachidonic acid-containing phospholipids, thereby providing substrate for the multiple enzymes of the arachidonic acid cascade.

The products of the arachidonic acid cascade are varied. These products include prostaglandins, thromboxanes, leukotrienes, and other hydroxylated derivatives of arachidonic acid. All of the foregoing are referred to as "eicosanoids." While generally the products of the cascade are beneficial, in certain disease processes and other conditions the excessive production of eicosanoids induces deleterious consequences such as inflammation (see paper by N. A. Plummer, et al.; abstracted in Journal of Investigative Dermatology, 68, p. 246 (1977)); erythema (N. A. Plummer, supra); platelet aggregation (B. B. Vargaftig, J. Pharm. Pharmacol., 29, pp. 222-228 (1977)); and the release of SRS-A (slow reacting substance-anaphylaxis), a known mediator of allergic responses. The inhibition of phospholipase A2 prevents these and similar conditions mediated by the action of this enzyme.

Some inhibitors of phospholipase A2 are known. R. J. Flower and G. J. Blackwell have shown that certain anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. See Nature, 278, p. 456 (1979). These steroids are not direct inhibitors of phospholipase A2, but rather stimulate the synthesis of a phospholipase inhibiting factor called lipocortin, lipomodulin, or macrocortin.

Some examples of direct phospholipase A2 inhibition are known. Indomethacin, a drug with anti-inflammatory properties, has been shown to inhibit phospholipase A2 enzymes. See K. L. Kaplan, et al., Proc. Natl. Acad. Sci., 75, pp. 2955-2958 (1978).

2

Indomethacin has been shown to inhibit phospholipase A2 enzymes, isolated respectively from the venoms of Russell's Viper, Crotalus adamanteus, and bee, and from pig pancreas. Certain local anesthetics have been shown to inhibit phospholipase A2 activity by competing with calcium ion, which appears to be a requirement for phospholipase activity. See W. Vogt, Advances in Prostaglandin and Thromboxane Research, 3, p. 89 (1978) and E. Vallee et al.

J. Pharm. Pharmacol., 31, pp. 588-92 (1974). Bromphenacyl bromide has been shown to inhibit phospholipase A2 by acylating a histidine residue which is at the active site of the enzyme. See M. Roberts, et al., J. of Biol. Chem., 252, pp. 2405-2411 (1977). R. Blackwell, et al., British J. Pharmacy, 62, p. 79-89 (1978) has disclosed that meprazine inhibits the activity of phospholipase A2 derived from perfused guinea pig lung. Certain butyrophilones are disclosed as phospholipase A2 inhibitors in U.S. Pat. No. 4,239,780. D. P. Wallach and V. J. R. Brown, Bioch. Pharmacol., 30, pp. 1315-24 (1981) also refer to several compounds that inhibit phospholipase A2.

Some of the steroids employed for synthesizing compound of the present invention and useful in some of the methods of treatment are known. See the doctoral thesis, L. J. Griggs, "Part I. Synthetic Approaches to 5- and 16-Thiaestrone. Part II. Estrone with a Diazacholesterol Side Chain," University of Michigan (1965). These compounds are stated therein to be potential hypocholesterolemic agents. U.S. Pat. No. 3,370,070 discloses similar steroid compounds which are useful as hypocholesterolemic agents and as antibacterial, anti-protozoal, and anti-algal agents.

Some of the steroid compounds herein are also referred to in U.S. Pat. No. 3,284,475 and in P. D. Klimstra, et al., "Hypocholesterolemic Agents. VI. A-And B-Ring-Modified Azacholesterols", J. Med. Chem., 9, pp. 323-26 (1966).


The present invention also relates to antidiabetic agents. Hyperglycemia refers to a condition commonly found in patients suffering from mature-onset diabetes mellitus and other diseases in which impairment of pancreatic function is a consequence thereof. Accordingly, hyper-glycemic patients are those exhibiting elevated serum glucose levels. Failure to adequately control such elevated serum glucose levels has been associated in such patients with untoward cardiovascular effects (myocardioischemia, stroke, and peripheral vascular diseases), lethargy, coma, blindness, kidney failure and even death.

While conventional treatment for these hyperglycemic conditions may include diet (e.g. restriction of carbohydrate intake) and insulin injection, one important means of treating such patients is with oral antidiabetic agents such as those disclosed herein.

SUMMARY OF THE INVENTION





The present invention relates to cyclic hydrocarbons of formula I wherein:

A compound of the formula



wherein:

(I) Z is



(1) wherein D is

(a) H, (b) CH_3 , or (c) no bond;

(2) wherein E and J are

(a) H, (b) R_5O , or (c) $-\text{N}(\text{CH}_3)-(\text{CH}_2)_3-\text{N}(\text{CH}_3)_2$ with the provisos that when E is H, the 5,6 bond is saturated and that when J is H, X_2 and X_3 are H;

(3) wherein G is

(a) nothing, or (b) $\rightarrow\text{O}$;

(4) wherein R_5 is

(a) H, (b) C1-C3 alkyl, (c) benzyl, (d) acyl, (e) $\text{C}(\text{O})\text{H}$, (f) $\text{HOCH}_2\text{CH}(\text{OH})\text{CH}_2$, (g) $\text{R}_4-\text{OC}-(\text{O})\text{CH}_2$;

(5) wherein X_2 and X_3 are

(a) H, (b) NO_2 , (c) NH_2 , (d) OH, or (e) halogen;

A. C8-C20 cycloalkyl, C. 2- or 4-cyclohexylcyclohexyl, D. 4-bicyclohexylcyclohexyl, E. 4-bicyclohexenylcyclohexyl, F. 3-cyclopentylcyclopentyl, G. 1-, 3- or 4-(2-deahydronaphthyl)cyclohexyl, H. 1- or 2-tetradecahydroanthracenyl, I. 2- or 3-tetradecahydrophenanthrenyl, J. 1- or 2-dodecahydro-1H-phenyl, K. 1- or 2 hexadecahydrophenyl, L. 1- or 2-octadecahydrotriphenylenyl, M. 1- or 2-octadecahydrochrysene, N. 1- or 2-octadecahydronaphthalenyl, O. phenylcyclohexyl, P. adamantyl, Q. pyrenyl, R. 3-fluorobiphenyl, or S. 1- or 2-decalinyl;

II. wherein X_1 is

A. NR_1 , B. NR_1R_{13} , C. $\text{N}^+\text{R}_1\text{R}_1\text{R}_{13}\text{X}^-$, or D. $-\text{O}-\text{C}(\text{O})-\text{CH}((\text{CH}_2)_3-\text{NH}_2)(\text{NH}_2)$;

1. wherein X^- is a pharmaceutically acceptable anion;

2. wherein R_{13} is

a. methyl, or b. $\rightarrow\text{O}$;

3. wherein R, is

a. H, b. $-\text{CHO}$, c. $-\text{COCH}_3$, d. C1-C6 alkyl, e. $-(\text{CH}_2)_p-\text{CO}_2\text{R}_4$, f. $-\text{CH}_2\text{CH}=\text{CH}_2$, g. $-(\text{CH}_2)_p-\text{X}_4$, h. $-(\text{CH}_2)_m-\text{N}(\text{R}_6)(\text{R}_7)$, i. $-(\text{CH}_2)_p-\text{O}(\text{CH}_2)_p-\text{N}(\text{R}_6)(\text{R}_7)$, j. $-(\text{CH}_2)_p-$
 $-Y-\text{C}(=\text{NH})-\text{NH}_2$, k. $-(\text{CH}_2)_q-\text{CH}(\text{NH}_2)-$
 COOR_{16} , l. $-(\text{CH}_2)_p-\text{N}=\text{C}(\text{R}_{14})(\text{R}_{15})$, m.
 $-(\text{CH}_2)_p-\text{NH}-\text{C}(\text{CH}_3)_2-\text{CH}_2-\text{C}(\text{O})-\text{CH}_3$,

5

10

15

20

25

30

35







40

45

50

55

60



(1) wherein R_4 is

(a) H, or (b) C1-C2 alkyl;

(2) wherein X_4 is

(a) OH, (b) OCH_3 , (c) OC_2H_5 , (d) $\text{OCH}_2\text{CH}_2\text{OH}$, (e) OTs,
(f) OMs, (g) Cl, (h) Br, (i) aziridinyl, or (k)





i) wherein R_{12} is

ii)(a) C1-C2 alkyl, ii)(b) benzyl, ii)(c) CH_2Cl , ii)(d) \rightarrow
O, ii)(e) $\text{CH}_2\text{COOC}_2\text{H}_5$, or ii)(f) C3-C18 straight
chain alkyl;

(3) wherein R_6 is

(a) H, (b) C1-C13 alkyl, (c) benzyl, (d) phenyl, (e) $-(\text{CH}_2)_p-\text{N}(\text{R}_{10})(\text{R}_{11})$, (f) $\text{C}(\text{O})\text{CH}_3$, (g)






i) wherein R_{10} and R_{11} are

i)(a) H, i)(b) C1-C2 alkyl, or i)(c) $(CH_2)_3-NH_2$;


ii) wherein R_{10} and R_{11} together are



(4) wherein R_7 is


(a) H, (b) C1-C2 alkyl, (c) $-(CH_2)_p-N(R_{10})(R_{11})$, or (d) CHO;

(5) wherein R_6 and R_7 together are



i) wherein X_5 is

i)(a) O, i)(b) NH, i)(c) NCH₃, or i)(d) $N(CH_2)_qNH_2$;



(6) wherein Y is

(a) NH, or (b) S;

(7) wherein R_8 is

(a) H, (b) C1-C2 alkyl, (c) OCH₃, (d) NO₂, (e) NH₂, (f) $NHCOCH_3$, (g) CN, (h) CH_2NH_2 , (i) $CONH_2$, (j) Cl, (k)

Br, or (l) $COOCH_3$;

(8) wherein R_9 is

(a) H, (b) methyl, (c) benzyl, or (d) $-(CH_2)_pN(R_{10})(R_{11})$;

(9) wherein R_{14} is

(a) H, or (b) C1-C6 alkyl;

(10) wherein R_{15} is C1-C6 alkyl;

(11) wherein R_{16} is

(a) H, or

(b) C1-C4 alkyl;

(12) wherein X_7 and X_8 are the same or different and are

(a) H, (b) CH₃, (c) CF₃, (d) halogen, (e) OH, (f) OCH₃, (g)

NO₂, (h) NH₂, (i) NHR₁, (j) NR₁R₂, (k) $-CH_2NH_2$, (l)


$\overline{-CH_2NHR_2}$, (m) $\overline{-SO_2N(R_3)(R_4)}$, (n) $\overline{-CO_2R_4}$, (o)

$CON(R_3)(R_4)$, (p) $CH_2N(R_3)(R_4)$, or (q) tetrazolyl;

6

III. wherein R_1 is
 A. H, B. C1-C4 alkyl, C. benzyl, D. $-(CH_2)_p-$
 $N(R_6)(R_7)$,

5




10

N($\rightarrow O$)(R₆)(R₇), H. $-(CH_2)_pN^+(CH_2-Ph)(R_6)(R_7)$, or I.
 $-(CH_2)_pN^+(CH_3)(R_6)(R_7)$, J. nothing;


IV. wherein R_1 and R_2 together are

15



I. wherein X_5 is

a. O, b. NH, c. NCH₃, or d. S;



20

2. wherein X_9 is

a. O, b. NH, or c. NCH₃;

V. wherein R_3 is

A. H, B. C1-C2 alkyl, or C. CH₂OH;

wherein m is 2-8;

wherein n is 0-1;

wherein p is 2-8;

wherein q is 2-4;

wherein r is 1-8;

wherein s is 2-8; and

pharmacologically acceptable salts thereof;

30

with the proviso that when n is 1 and R_1 is $-(CH_2)_m-$
 $N(R_6)(R_7)$ wherein m is 2 or 3 and R_1 is H or CH₃, or when
 R_2 is $-(CH_2)_m-N(R_6)(R_7)$ wherein m is 2 or 3 and R_1 is H,
 CH₃, CHO, or CH₃CO, then R_6 and R_7 cannot both be
 hydrogen, methyl, or ethyl;


35

and with the proviso that when n is 0 and R_1 is
 $-(CH_2)_m-N(R_6)(R_7)$ wherein m is 2 or 3 and R_2 is H or
 CH₃, or when R_1 is $-(CH_2)_m-N(R_6)(R_7)$ wherein m is 2
 or 3 and R_2 is H, CH₃, CHO, or CH₃CO, then R_6 and R_7
 cannot both be hydrogen, methyl, or ethyl, *or* isopropyl;


and with the proviso that when n is 0 and one of R_1 and
 R_2 is $-(CH_2)_m-N(R_6)(R_7)$ wherein m is 3, and the other
 is H or methyl, then R_6 and R_7 cannot be H or methyl;

and with the proviso that when n is 0 and XI is NR₁, then
 R_1 cannot be CHO when R_2 is H;
 for each of the foregoing provisos, Z is



55



The material constituting a full disclosure of these compounds, their use and preparation is described in U.S. Pat. No. 5,196,542, issued 23 Mar. 1993, incorporated by reference herein.

CHART A

9
continued
CHART A

**10****CHART B**


30

35

40



45

50


CHART C

55

continued
CHART C

**CHART D**

11
continued
CHARTD



It is claimed:

1. A compound selected from the group consisting of:
 a) 3-hydroxy-17 β -((3-trifluoromethyl)phenylmethyl)amino)-estra-1,3,5(10)-triene tetrahydrofuran solvate; 30
 b) 3-methoxy-17 β -((2-(4-chlorophenyl)ethyl)amino)-estra-1,3,5(10)-triene;
 c) 3-(2-(2,3-dihydroxypropoxy)-17 β -((4-chlorophenylmethyl)amino)-estra-1,3,5(10)-triene; 35
 d) 3-methoxy-17 β -((4-methoxycarbonylphenylmethyl)amino)-estra-1,3,5(10)-triene;
 e) 3-methoxy-17 β -((4-bromophenylmethyl)amino)-estra-1,3,5(10)-triene; 40
 f) 3-methoxy-17 β -((3-chlorophenylmethyl)amino)-estra-1,3,5(10)-triene;
 g) 3-methoxy-17 β -((3-phenylpropyl)amino)-estra-1,3,5(10)-triene;
 h) 3-methoxy-17 β -((4-phenylbutyl)amino)-estra-1,3,5(10)-triene; 45
 i) 3-methoxy-17 β -((4-methylphenylmethyl)amino)-estra-1,3,5(10)-triene;
 j) 3-methoxy-17 β -((1-phenylethyl)amino)-estra-1,3,5(10)-triene;
 l) 3-methoxy-N-methyl-17 β -((3-trifluoromethyl)phenylmethyl)amino)-estra-1,3,5(10)-triene; 55
 m) 3-methoxy-N-ethyl-17 β -((3-trifluoromethyl)phenylmethyl)amino)-estra-1,3,5(10)-triene;
 n) 3-methoxy-N-(propyl)-17 β -((3-trifluoromethyl)phenylmethyl)amino)-estra-1,3,5(10)-triene;
 o) 3-methoxy-N-(3-methylbutyl)-17 β -((3-trifluoromethyl)phenylmethyl)amino)-estra-1,3,5(10)-triene hydrochloride; 60
 p) 3-methoxy-N-(octyl)-17 β -((3-trifluoromethyl)phenylmethyl)amino)-estra-1,3,5(10)-triene hydrochloride;
 q) 3-methoxy-N-(tetradecyl)-17 β -((3-trifluoromethyl)phenylmethyl)amino)-estra-1,3,5(10)-triene; 65
 r) 3-methoxy-N-ethyl-17 β -((4-chlorophenylmethyl)amino)-estra-1,3,5(10)-triene;

12

- § 3-methoxy-N-ethyl-17 β -((2-(4-aminosulfonylphenyl)ethyl)amino)-estra-1,3,5(10)-triene;
- † 3-methoxy-N-ethyl-17 β -((2-trifluoromethyl)phenylmethyl)amino)-estra-1,3,5(10)-triene;
- ‡ 3-methoxy-N-(3-phenylpropyl)-17 β -(3-phenylpropyl)amino)-estra-1,3,5(10)-triene;

and pharmacologically acceptable salts thereof.

2. A compound selected from the group consisting of:
 d) 17 β -((2-(4-aminosulfonylphenyl)ethyl)amino)androstane;
 e) (20s)-20-N-(3-trifluoromethyl)benzyl-19-norpregna-1,3,5(10)-triene-20-amine.
3. A compound selected from the group consisting of:
 q) N-benzyl-3-methoxyestra-1,3,5(10)-trien-17 β -amine;
 u) 17 β -(phenylamino)androst-5-en-3 α -ol hydrate;
 w) 3-methoxy-17 β -((4-chlorophenyl)amino)estra-1,3,5(10)-triene;
- x) 3-methoxy-17 β -((4-methoxyphenyl)amino)estra-1,3,5(10)-triene;
- y) 3-methoxy-17 β -((3-trifluoromethyl)phenyl)amino)-estra-1,3,5(10)-triene;
- z) 3-methoxy-17 β -((4-methoxycarbonyl)phenylamino)-estra-1,3,5(10)-triene;
- al) 3-methoxy-N-17 β -((phenylmethyl)amino)estra-1,3,5(10)-triene;
- bl) 3-methoxy-N-ethyl-17 β -((phenylmethyl)amino)estra-1,3,5(10)-triene;
- c1) 17 β -9(phenylmethyl)amino)androst-5-en-3 β -ol ethanol solvate;
- d1) 17 β -((2-furylmethyl)amino)androst-5-en-3 β -ol;
- el) 17 β -9(4-chlorophenylmethyl)amino)androst-5-en-3 β -ol;
- f1) 17 β -((2-(4-aminosulfonylphenyl)ethyl)amino)androst-5-en-3 β -ol;
- h1) 17 β -9((3-trifluoromethyl)phenylmethyl)amino)androst-5-en-3 β -ol;
- i1) 3-methoxy-17 β -((4-chlorophenylmethyl)amino)estra-1,3,5(10)-triene;
- j1) 3-methoxy-17 β -((3-trifluoromethyl)phenylmethyl)amino)estra-1,3,5(10)-triene;
- k1) 3-methoxy-17 β -((4-methoxyphenylmethyl)amino)estra-1,3,5(10)-triene;
- l1) 3-methoxy-17 β -((4-trifluoromethyl)phenylmethyl)amino)estra-1,3,5(10)-triene;
- n1) 3-methoxy-17 β -((2-(4-aminosulfonylphenyl)ethyl)amino)estra-1,3,5(10)-triene;
- o1) 3-methoxy-17 β -((4-aminosulfonylphenylmethyl)amino)estra-1,3,5(10)-triene;
- q1) 3-methoxy-17 β -((2-trifluoromethyl)phenylmethyl)amino)estra-1,3,5(10)-triene;
- s1) 3-methoxy-17 β -((4-fluorophenylmethyl)amino)estra-1,3,5(10)-triene;
- t1) 3-methoxy-17 β -((3,4-dichlorophenylmethyl)amino)estra-1,3,5(10)-triene;
- u1) 3-methoxy-17 β -((2,4-dichlorophenylmethyl)amino)estra-1,3,5(10)-triene;
- v1) 3-methoxy-17 β -((2-chlorophenylmethyl)amino)estra-1,3,5(10)-triene;
- b2) N-benzylestra-1,3,5(10)-trien-17 β -amine;
- c2) N-(3-trifluoromethylphenyl)-3-methoxyestra-1,3,5(10)-trien-17 β -amine;

13

d2) N-(4-methoxycarbonylphenyl)-3-methoxyestra-1,3,
5(10)-trien-17 β -amine;
and pharmacologically acceptable salts thereof.
4. A compound selected from the group consisting of:
c) N-diphenylmethyl-3-methoxyestra-1,3,5(10)-trien-⁵
17 β -amine;
d) N-(2-(2'-phenyl)ethyl)-3-methoxyestra-1,3,5(10)-
trien-17 β -amine;

14

e) (1'S,2'S)-N-(1',3'-dihydroxy-1'-phenyl)isopropyl-3-
methoxyestra-1,3,5(10)-triene-17 β -amine;
f) N-(2'-(4"-hydroxyphenyl)ethyl)-3-methoxyestra-1,3,
5(10)-trien-17 β -amine;
g) N-benzyl-5 α -androstan-17 β -amine;
and pharmacologically acceptable salts thereof.

* * * * *